NASDAQ
05.12.24
21:55 Uhr
2,310 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Lexaria Bioscience CEO erwirbt Aktien im Wert von 118.391 US-Dollar | 1 | Investing.com Deutsch | ||
| 26.11. | Lexaria Bioscience Corp. - 10-K, Annual Report | - | SEC Filings | ||
| 26.11. | Lexaria Bioscience Corp.: Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs | 189 | ACCESSWIRE | Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come KELOWNA... ► Artikel lesen | |
| 25.11. | Lexaria Bioscience Corp.: Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled | 148 | ACCESSWIRE | DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November 25, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company"... ► Artikel lesen | |
| LEXARIA BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 20.11. | Lexaria Bioscience Corp.: ALL Study Groups using DehydraTECH Processing Outperform Rybelsus in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study | 203 | ACCESSWIRE | DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65%... ► Artikel lesen | |
| 14.11. | Lexaria startet einzigartige Studie zur Arzneimittelverteilung | 2 | Investing.com Deutsch | ||
| 14.11. | Lexaria Bioscience Corp.: Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study | 143 | ACCESSWIRE | World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the... ► Artikel lesen | |
| 13.11. | Lexaria Bioscience Corp.: Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss | 233 | ACCESSWIRE | DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global... ► Artikel lesen | |
| 07.11. | Lexaria Bioscience Corp.: Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments | 248 | ACCESSWIRE | DehydraTECH for GLP-1 being optimized for global pharmaceutical use KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a... ► Artikel lesen | |
| 24.10. | Lexaria meldet vielversprechende Ergebnisse zur Blutzuckerkontrolle in Tierstudie | 4 | Investing.com Deutsch | ||
| 24.10. | Lexaria reports promising blood sugar control in animal study | 2 | Investing.com | ||
| 24.10. | Lexaria Bioscience Corp.: Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study | 198 | ACCESSWIRE | DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)... ► Artikel lesen | |
| 22.10. | Lexaria vermeldet Fortschritte bei Studie zu Abnehmmittel | 2 | Investing.com Deutsch | ||
| 22.10. | Lexaria Bioscience Corp.: Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study | 179 | ACCESSWIRE | DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groupsAccelerated rates of weight loss were experienced during the final 4 weeks of the study in all... ► Artikel lesen | |
| 18.10. | Lexaria Bioscience Corp. legt Termin für kombinierte Jahres- und Sonderversammlung fest | 1 | Investing.com Deutsch | ||
| 18.10. | Lexaria Bioscience Corp. sets date for combined annual and special meeting | 1 | Investing.com | ||
| 16.10. | Lexaria Bioscience Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.10. | Lexaria Bioscience Corp.: Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | 272 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / October 16, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed... ► Artikel lesen | |
| 15.10. | Lexaria Bioscience Corp.: Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | 240 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / October 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it... ► Artikel lesen | |
| 09.10. | Lexaria Bioscience Corp.: Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing | 249 | ACCESSWIRE | DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / October 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company"... ► Artikel lesen |
Seite:
1 2 3 4 Weiter >>
78 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EMEIS | 5,385 | +0,90 % | emeis: Upturn in Performance Confirmed in Third-Quarter 2024 | Revenue up +8.3%, occupancy rate up +2.6 points
Regulatory News:
emeis (Paris:EMEIS):
Growth in all core activities and in all geographical areas (revenue and occupancy rate)
Solid... ► Artikel lesen | |
| EMPOWER CLINICS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.07.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 30.07.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.07.2024ISIN NameCA29246V2030 EMPOWER... ► Artikel lesen | |
| NANO-X IMAGING | 6,230 | 0,00 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication | Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication... ► Artikel lesen | |
| GLOBAL HEMP GROUP | 0,010 | 0,00 % | Global Hemp Group Inc (2): Global Hemp appoints Cheery as CFO | ||
| BUTTERFLY NETWORK | 3,315 | 0,00 % | Cathie Wood's ARK buys ABSI stock, sells BFLY and SNTI | ||
| GOODRX | 4,910 | 0,00 % | How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals | ||
| TALKSPACE | 3,535 | 0,00 % | Espresa Partners with Talkspace to Boost Employee Well-Being with Accessible Mental Health Benefits | Espresa has partnered with Talkspace to expand mental health support for employees. Through Espresa's platform, clients now have access to Talkspace's 5,000+ licensed therapists, offering secure, on-demand... ► Artikel lesen | |
| CARMAT | 1,032 | +0,39 % | Successful first "Aeson European User Meeting", marking an important step in the deployment of CARMAT's artificial heart | More than 100 healthcare professionals from 41 hospitals and 10 countries rallied to share their experiences of the Aeson® artificial heart All hospitals taking part in the event confirmed... ► Artikel lesen | |
| JOINT CORP | 11,710 | +0,09 % | The Joint Corp. Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SCOTTSDALE, Ariz., Oct. 15, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT) ("The Joint or "the Company"), the nation's largest franchisor of chiropractic care through The Joint Chiropractic®... ► Artikel lesen | |
| MIMEDX | 9,470 | -1,25 % | MDXG-Aktie erreicht 52-Wochen-Hoch bei 9,66 US-Dollar | ||
| HYPERFINE | 0,980 | +1,02 % | Hyperfine, Inc. Reports Third Quarter 2024 Financial Results | GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 93,60 | 0,00 % | 5 Analysts Assess PROCEPT BioRobotics: What You Need To Know | ||
| BIOMERICA | 0,361 | -2,85 % | Biomerica, Inc.: Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements | IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day... ► Artikel lesen | |
| ATRICURE | 34,060 | 0,00 % | Pre-market Movers: ASP Isotopes, NerdWallet, Reddit, AtriCure, Qorvo | OLATHE (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green ASP Isotopes Inc. (ASPI) is up over 44% at $8.33.
NerdWallet... ► Artikel lesen | |
| PROGYNY | 15,015 | +0,91 % | Here's What Led to a Sharp Drop in Progyny's (PGNY) Share Price |
Das Unternehmen LEXARIA BIOSCIENCE CORP kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 2,310 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXARIA BIOSCIENCE CORP finden Sie auf Wallstreet Online.
